BillionToOne vs Veracyte
BLLN and VCYT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BLLN and VCYT compare
BillionToOne is the larger company, worth 2.5 times as much as Veracyte ($5.0B against $2.0B).
BillionToOne grew revenue faster over the last twelve months (71.9% versus 17.5% for Veracyte).
Veracyte keeps more of each dollar of sales as profit, with a net margin of 21.8% compared with 11.3% at BillionToOne.
Veracyte scores higher on the StockData Score (17 against 11 for BillionToOne), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BLLN | VCYT |
|---|---|---|
| Size and price | ||
| Market cap | $5.0B | $2.0B |
| Share price | $105.15 | $24.33 |
| Change, 1 year | 3.3% | −42.5% |
| Change, 5 years | – | −50.6% |
| Beta (5Y) | −0.04 | 1.78 |
| Employees | 713 | 755 |
| StockData Score | ||
| Total score | 11 | 17 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 3 | 4 (better) |
| Performance score | 2 | 3 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 15.8× |
| P/S | 11.4× | 3.4× (better) |
| P/B | 8.8× | 1.4× (better) |
| EV/EBITDA | 84.8× | 14.5× (better) |
| P/FCF | 146× | 12.1× (better) |
| FCF yield | 0.68% | 8.3% (better) |
| Fair value | – | $36.85 |
| Margin of safety | – | 34.0% |
| Growth | ||
| Revenue growth (TTM) | 71.9% (better) | 17.5% |
| Revenue growth, 5Y average | – | 34.5% |
| Net income growth (TTM) | – | 318% |
| EPS growth (TTM) | – | 305% |
| Profitability | ||
| Gross margin | 71.4% | 72.0% (better) |
| Operating margin | 10.2% | 17.1% (better) |
| Net margin | 11.3% | 21.8% (better) |
| FCF margin | 7.8% | 27.8% (better) |
| Return on equity | 30.2% (better) | 9.4% |
| Return on invested capital | – | 9.1% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | 1655× | – |
| Current ratio | 11.25 (better) | 5.56 |
| Altman Z-score | 16.67 (better) | 8.99 |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 32.4% | 111% |
| Held by insiders | 55.7% | 1.7% |
| Insider net buying, 12 months | −$58.5M | −$18.6M (better) |
| Short interest, % of float | 14.2% | 12.1% |
Go deeper
- BLLN stock overview
- BLLN income statement
- BLLN valuation and score
- VCYT stock overview
- VCYT income statement
- VCYT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.